Syncope, a transient loss of consciousness due to global cerebral hypoperfusion, presents a diagnostic challenge in clinical practice. This article aims to provide a comprehensive approach to diagnosing and managing syncope, enhancing patient care and outcomes.
Diagnosing syncope begins with a thorough history and physical examination. Cardiovascular and neurological evaluations are crucial to identify potential causes. The San Francisco Syncope Rule and the OESIL risk score can aid in risk stratification, guiding further diagnostic testing.
Electrocardiography (ECG) is an essential initial diagnostic tool. It can reveal arrhythmias, structural heart disease, or ion channelopathies, which are common causes of syncope. However, a normal ECG does not rule out cardiac syncope, necessitating further evaluation.
When initial evaluations are inconclusive, advanced diagnostic tools such as echocardiography, exercise stress testing, and cardiac monitoring may be required. Tilt-table testing and carotid sinus massage can be useful in diagnosing neurally mediated and carotid sinus syncope, respectively.
Management of syncope is tailored to the underlying cause. In cardiac syncope, treatment may involve medication, cardiac devices, or ablation. For reflex syncope, patient education, physical counterpressure maneuvers, and pharmacotherapy are effective. In orthostatic hypotension, management includes volume expansion, compression stockings, and medication.
Regular follow-up is vital to assess treatment response and adjust management. While the prognosis of syncope is generally good, it can be life-threatening if due to a cardiac cause, underscoring the importance of accurate diagnosis and appropriate management.
In conclusion, syncope presents a diagnostic and therapeutic challenge. A comprehensive approach, incorporating a thorough history, physical examination, appropriate diagnostic testing, and tailored management, can optimize patient outcomes.
1.
Year in Review: Non-Small Cell Lung Cancer
2.
Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat
3.
The need for more Latinx participants in Alzheimer's trials is urgent.
4.
Why palliative care goes hand in hand with treatment for people with cancer: Q&A
5.
MRD-Guided Azacitidine May Delay Relapse in AML, MDS
1.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
2.
The Danger of Methemoglobinemia and How to Prevent It
3.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
4.
Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain
5.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Thromboprophylaxis In Medical Settings
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation